Scaling-up collaborative tuberculosis and human immunodeficiency virus (TB/HIV) activities in the WHO European region is a priority. The region accounts for 6% of the global burden of TB and has the highest levels of drug-resistant tuberculosis in the world. Approximately 2.4 million children and adults were living with HIV in the region in 2008 with 1.5 million living in Eastern Europe and Central Asian countries, and the region faces the fastest growing HIV epidemic in the world. However, low and middle income countries in the region have amongst the lowest coverage with antiretroviral therapy (ART) globally. The first European TB/HIV regional meeting “Accelerating the implementation of collaborative TB/HIV activities in the WHO European Region” was organized by the World Health Organization (Headquarters and Regional Office for Europe) in collaboration with the TB/HIV Working Group of the Stop TB Partnership prior to the XVIII International AIDS Conference in Vienna in July 2010.

A total of 186 people from 37 countries participated to the meeting with representation from all of the 18 high TB burden countries and those countries most seriously affected by HIV, including those with the highest population prevalence from the region. Participants discussed how to strengthen collaboration and coordination between programmes, how to address drug-resistant TB, and how to provide integrated and comprehensive care to most at risk populations such as people who use drugs, migrants and prisoners. Participants also shared experiences and best practices to inform recommendations to accelerate the implementation of nationwide scale-up of collaborative activities.

National TB, HIV and harm reduction programme managers as well as officials from the penitentiary system were joined by a broad range of TB and HIV/AIDS stakeholders active in the WHO European region, members of the TB/HIV Working Group, and representatives of non-governmental and civil society organizations.

This report summarizes key outcomes, conclusions and recommendations of the meeting.
The WHO European region contributes to 6% of the global burden of tuberculosis (TB). Eighteen countries\(^1\) share 86% of the regional TB burden reporting notification rates between 11 and 72 per 100,000 populations. The region is also facing dramatic increase of HIV infection mainly driven by injecting drug use in Eastern European and Central Asian countries. In 2008, the regional prevalence of HIV among TB patients was estimated at 5.6%. Though nearly 80% of all TB patients were tested for HIV that same year, only less than half (48%) of the estimated number of people living with HIV and TB in the region were identified. Of those found HIV positive, 61% and 28% were receiving cotrimoxazole preventive therapy and ART respectively. Overall, the region has the second lowest level of access to ART for people in need of it (23%). TB case finding among people living with HIV and provision of isoniazid preventive therapy remain very low. Moreover, both epidemics are spreading within most at risk and highly stigmatized populations such as people who inject drugs, prisoners and migrants, living outside of the system, most often without residence permits and therefore with restricted or no access to health services. Uptake of HIV testing and access to antiretroviral therapy is insufficient in these marginalized groups.

**Changing commitments into action: the missing link**

There are several regional strategies and political commitments to address the TB and HIV dual epidemic in the European region including the Berlin Declaration on Tuberculosis, the 2007-2015 plan to Stop TB in 18 high-priority countries and the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia. At the global level, prevention, diagnosis and treatment of TB are components of the WHO/UNAIDS essential package to prevent and treat HIV in people who inject drugs. This essential package has been endorsed at the highest level by, for example, the Economic and Social Council (ECOSOC) and the UNAIDS programme coordinating board.

\(^1\) Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russian Federation, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan.

### Implementation of TB/HIV collaborative activities: where are we?

We, the Ministers of Member States note with concern that in the Region, TB is the most prevalent cause of illness and mortality in people living with HIV/AIDS, and few countries address TB/HIV co-infection in a comprehensive manner. The Berlin Declaration on Tuberculosis, WHO European Ministerial Forum, 2007
Since 2002, Eastern European and Central Asian countries have received almost 1 billion USD for TB/HIV collaborative activities from the Global Fund to fight AIDS, Tuberculosis and Malaria - from 0.1 million to Bulgaria to 19 million USD to the Republic of Moldova. Such availability of funding coupled with the political commitments should offer an opportunity to mitigate the problem in the region. Resources should also be available from internal sources and plans should include a clear description of the collaboration between TB control and HIV/AIDS programmes in providing integrated TB and HIV services. Strategic advocacy is needed to raise the profile of TB/HIV among politicians and decision-makers and to promote the delivery of integrated TB/HIV services including in harm reduction programmes and in prison settings.

### HIV testing for TB patients and suspects: the gateway for HIV treatment and care

Although the region is making progress in the provision of HIV testing for TB patients, there is a wide difference among countries in the proportion of TB patients that received the test. HIV testing is not yet available for all TB patients and is not yet systematically linked to HIV care and treatment, including antiretroviral therapy. In Central Asian countries, more than a third of people living with HIV were estimated to die from TB in 2009. Potential reasons include excessive verticality of and almost non-existent collaboration between the TB and HIV/AIDS programmes with poor understanding of each other’s role. Also, these countries are often characterized by non-existent deliveries of integrated TB and HIV services, poor exchanges of information between HIV and TB health care workers and difficult access to voluntary, free-of-charge and confidential HIV testing and counselling services, all of which results in late diagnosis and delayed provision of HIV treatment and care and in late diagnosis of TB. This is even more applicable to most at risk groups, such as people who use drugs, migrants and prisoners. Likewise, HIV testing is not routinely offered to patients who present with symptoms and signs suggestive of TB (TB suspects) that further delays the access to HIV care.

### Integrated delivery of TB and HIV services averts unnecessary mortality

Prevention, diagnosis and clinical management of TB disease in people living with HIV remains challenging despite clear international guidelines. In particular, the rates of undiagnosed TB in people living with HIV, including people who inject drugs, are very high as illustrated by post-mortem studies in Ukraine and in the Russian Federation where

---

**Excessive verticality: a bottleneck for quality TB and HIV services**

In many countries of the Region, if not all, the TB and HIV/AIDS programmes are run separately with their own management and service delivery mechanisms. Similarly the provision of harm reduction and prison health services are independently carried out by separate entities without formal or effective channels for communication and collaboration. Because of the intertwined nature of TB, HIV, injecting drug use and detention in the region, collaboration and coordination between TB, HIV/AIDS, harm reduction programmes, criminal justice system and civil society is crucial for effective and integrated response to TB and HIV. The establishment or revitalization of effective TB/HIV coordinating bodies at national, regional or local levels is crucial. More emphasis should be given to provide integrated TB and HIV services at all levels and the necessary programmatic and regulatory conditions need to be fulfilled as a matter of urgency.
over 40% of HIV deaths were related to TB. Tuberculosis remains the overwhelming single cause of death in people living with HIV in the region despite clear guidance to improve the diagnosis and management of TB in people living with HIV, including the provision of antiretroviral therapy. The 2010 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents recommend that all HIV-infected patients with active TB disease are eligible for antiretroviral therapy irrespective of CD4 count and that antiretroviral therapy should be started as soon as possible after initiation of TB treatment. The guidelines also recommend early initiation of antiretroviral therapy in all adolescents and adults including pregnant women with HIV infection and CD4 cell count ≤350 cells/mm3. The expansion of ART coverage is a powerful strategy to reduce HIV and TB associated morbidity and mortality, and incidence. Revision of national policies as well as appropriate training of staff is therefore critical to provide best standard of care for people living with HIV and TB.

**Scale-up harm reduction programmes that include opioid substitution therapy**

The provision of prevention, treatment and care services for people who inject drugs remains extremely low in Eastern European and central Asian countries: a recent systematic review shows that only 10% of people who inject drugs have access to needle and syringes programmes, that only 1 per 100 people who inject drugs receive opioid substitution therapy and only 1 per 100 people living with HIV and who inject drugs access antiretroviral therapy. Contrary to the belief of many health care workers, the adherence of people who use drugs to TB treatment and antiretroviral therapy can be as good as in non-drug users. A recent meta-analysis shows that rates of loss to follow-up and virological failure on antiretroviral therapy were similar in people who inject drugs and in people who do not. There is no reason that this should not apply to TB treatment. As mentioned by one meeting participant: “if there is one thing that people who use drugs are good at, that is taking drugs!”

Nationwide scale-up of opioid substitution therapy (OST) is still far away in the region. Four of the high TB burden countries (Armenia, Russian Federation, Turkmenistan and Uzbekistan) have not yet made OST available and in all other countries OST is provided through pilot-sized programmes with few people enrolled. Even Ukraine, with the highest number of people on OST in the region (5,000), is far from providing the recommended 40% coverage in a country of estimated hundreds of thousands of people who inject drugs. Furthermore, these programmes are usually provided by non-governmental organizations and externally funded.

**Provision of integrated services for TB, HIV and harm reduction is feasible in prison settings**

Prisoners and people living in places of detention are exposed to some of the highest risk for TB and HIV co-infection. Multi-drug resistant TB is also more common in prisons settings.

---


In the Republic of Moldova, TB/HIV services and harm reduction interventions including early TB case detection, directly observed TB treatment, voluntary counselling and testing, antiretroviral therapy, needles and syringes programmes, and psychosocial support are provided by a non-governmental organization with support of national authorities. However, challenges remain such as absence of rapid test to diagnose TB, low implementation of isoniazid preventive therapy, absence of opioid substitution therapy, and high rates of loss to follow-up after release from prison which is seen as a major contributor to poor treatment outcomes in many countries in Eastern Europe. The removal of passports as a result of imprisonment and the absence of a registered residency address upon release mean that ex-prisoners face difficulties to register for and continue TB or HIV treatment or any other medical services. In the Republic of Moldova, psycho-social support, incentives and DOTS supporter to encourage ex-prisoners to maintain a link with the health system on release are potential ways to reduce default from treatment and loss to follow up. Prisoners should obtain care equivalent to that provided to the civilian population, and care should be continuous on transfer in and out of places of detention.

**Monitoring and evaluation is crucially needed**

Meeting participants also discussed the need to coordinate the monitoring and evaluation of TB and HIV to improve follow-up of patients in care. In the Russian Federation, an integrated and linked monitoring system is in place tracking people living with HIV in care presenting to the various branches of the civil health system. However, the penitentiary system is separate and reconciliation between the two systems happens once every quarter. The separate monitoring system was highlighted as a bottleneck to care. In addition, the use of harmonized and internationally agreed TB/HIV indicators and standardized recording and reporting formats is crucial to assess progress in nationwide implementation of TB/HIV collaborative activities. Both TB and HIV/AIDS programmes should report the numbers of patients in care being treated for both TB and HIV. Data cross-checking is also important to validate data coming from the TB and HIV care registers.

**Country experiences**

Beyond the plenary presentations, country experiences in implementing collaborative TB/HIV activities were shared in an interactive forum with poster displays and discussions. Presentations were made by Armenia, Azerbaijan, Belarus, Estonia, Georgia, Netherlands, Republic of Moldova and the former Yugoslav Republic of Macedonia. They included activities run by ministries of health, academic institutions, partner organizations, technical agencies and non-governmental organizations. Country-level implementation is happening but still falls short of national coverage of all the 12 collaborative TB/HIV activities. There are no longer valid excuses for countries not to plan nationwide scale-up collaborative TB/HIV activities, particularly when clear policy recommendations exist since 2004.

---

Accelerating the implementation of collaborative TB/HIV activities in the WHO European Region

Armenia
With support and information, key stakeholders can commit to address TB/HIV issues in a collaborative way. To move this commitment into action, several steps are still needed: continuous involvement of TB/HIV advocates including communities most affected by TB and HIV in collaborative activities, scaling-up provider-initiated HIV testing for TB patients, improvement of the national monitoring and evaluation system to include TB/HIV indicators and the development of appropriate recording and reporting formats.

Azerbaijan
Government support is key to the implementation of collaborative TB/HIV activities. Management of HIV-infected TB patients by TB doctors was authorized by the Ministry of Health and several trainings were conducted for medical doctors and primary health care service providers. Challenges remain such as the lack of an appropriate monitoring and evaluation system, shortage of qualified health care workers and drugs, and poor awareness among patients and health care workers.

Belarus
More than half (55%) of HIV patients died of TB in 2009 compared to 17% in 2002 while the incidence of HIV-associated TB has increased by 7.5 fold from 2002 to 2009. The following groups have been identified as particularly at risk of both TB and HIV: people who inject drugs, alcoholics, former prisoners, and the unemployed. Knowing the country epidemic is important to implement appropriate interventions and reduce the burden of both TB and HIV.

Estonia
Collaborative TB/HIV activities are being implemented such as HIV testing of TB patients and TB screening among people living with HIV, co-treatment with anti-TB drugs, antiretroviral therapy and opioid substitution therapy if indicated, information to patients and training of medical doctors. These resulted in earlier detection of both TB disease and HIV infection, decreased default rate among HIV-infected TB patients and increased TB awareness among people living with HIV.

Georgia
The prevalence of active TB disease among people living with HIV is as high as 22% while latent TB infection was detected in up to 32.6% of patients. Prevalence of HIV among TB patients ranges from 1.7 to 2.2%.

A national TB/HIV strategic plan 2007-2011 has been developed and a TB/HIV working group has been established to ensure the effective implementation of collaborative activities such as TB screening, including TST and interferon gamma assays to detect latent TB infection, among people living with HIV, HIV testing for TB patients and universal and free access to both TB and HIV treatment.

Netherlands
Computer-based training on TB diagnosis and care for HIV/AIDS health care workers has been developed by Health[e]Foundation and piloted in Uganda. The learning format includes a 3-month computer based self study on or offline and a 3-day onsite workshop. TB[e] Education provides an opportunity to large groups of health care workers to study at their own pace on a wide range of TB-related topics. The programme will be further rolled-out in other parts of the world.

Republic of Moldova
Sperenta Terrei, a community-based organization in Balti where TB and HIV rates are higher than the national average, provides personalized TB treatment support to vulnerable patients. Defaulter rates are low where Sperenta Terrei operates: 4% whereas the national TB default rate is 11%. Treatment support from the community and practitioners is essential to treatment completion.

The former Yugoslav Republic of Macedonia
Despite a low burden of TB and HIV, joint TB/HIV activities are being implemented in the country. Information, education and communication on TB is provided to high risk groups, including people living with HIV by non-governmental organizations, HIV testing is offered to TB patients but which still needs to be scaled-up, and people living with HIV are screened for TB and given TB prophylaxis when indicated.
Accelerating the implementation of collaborative TB/HIV activities in the WHO European Region

Drug-resistant TB and HIV: the overlapping epidemics

In 2008, there were 440,000 cases of multi-drug resistant (MDR) TB cases worldwide and 150,000 deaths estimated to be due to MDR-TB. The WHO European region has the highest levels of drug-resistant TB in the world, with 1 in 4 new TB patients in some areas of Eastern Europe having MDR-TB. By March 2010, 24 countries of the region had reported at least one case of extensively drug resistant TB. To date, it has not been possible to show an association between HIV and MDR-TB at population level. However, new HIV infections are also on the rise in those countries with higher proportions of multi-resistant TB cases. Based on current data, HIV-infected TB patients in Estonia, Latvia and the Republic of Moldova appear to be more at risk of harbouring MDR-TB strains.

Examples of MDR-TB diagnostic and management were presented. In Latvia, routine TB care include sputum culture and drug susceptibility testing on solid media for all TB suspects while liquid media and line probe assays are used for groups at high risk of drug-resistant TB, including people living with HIV, in order to speed up the diagnosis. Regarding management, the challenge is to abandon the hospitalization of TB patients and to implement new models of patient care including home based treatment for both drug susceptible and drug resistant TB. The “Expand TB” project (EXPanding Access to New Diagnostic for TB) to assist selected countries with the introduction of the newly WHO endorsed TB diagnostic technologies (automated liquid culture and drug susceptibility testing, rapid immunoassay for MTB speciation and line probe assays) was also presented. It involves several international partners such as FIND, the Global Drug Facility, UNITAID, and the Global Laboratory Initiative. Eight countries in Eastern Europe and Central Asia, namely

Dr Sampaio said at the special plenary session on TB/HIV at the AIDS conference

Programme management of drug-resistant TB: urgent nationwide scale-up needed

Only a small proportion of MDR-TB cases are currently treated: about 10,000 MDR-TB patients worldwide were enrolled under the Green Light Committee (GLC) standards in 2009. To address the weak national and international responses to drug-resistant TB, a workshop was held in March 2010 in Geneva. Main barriers to MDR-TB scale-up were identified such as diagnostic capacity, drug procurement, insufficient human resources, and poor coordination of global players. Consensus was reached on the need to scale-up nationwide MDR-TB diagnostics and treatment and to include MDR-TB as part of regular TB control programme. Increased political commitment, country ownership, accountability, and harmonized monitoring and evaluation of patients wherever they are treated or not under GLC programme are crucially needed.

Examples of MDR-TB diagnostic and management were presented. In Latvia, routine TB care include sputum culture and drug susceptibility testing on solid media for all TB suspects while liquid media and line probe assays are used for groups at high risk of drug-resistant TB, including people living with HIV, in order to speed up the diagnosis. Regarding management, the challenge is to abandon the hospitalization of TB patients and to implement new models of patient care including home based treatment for both drug susceptible and drug resistant TB. The “Expand TB” project (EXPanding Access to New Diagnostic for TB) to assist selected countries with the introduction of the newly WHO endorsed TB diagnostic technologies (automated liquid culture and drug susceptibility testing, rapid immunoassay for MTB speciation and line probe assays) was also presented. It involves several international partners such as FIND, the Global Drug Facility, UNITAID, and the Global Laboratory Initiative. Eight countries in Eastern Europe and Central Asia, namely

---

7 Armenia, Azerbaijan, Belgium, Czech Republic, Estonia, France, Georgia, Germany, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Republic of Moldova, Romania, Russian Federation, Slovenia, Spain, Sweden, Tajikistan, Ukraine.

Belarus, the Republic of Moldova, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan and Tajikistan, have been targeted to benefit from the project. Countries are in various phases of implementation with some, like Uzbekistan, having already started to use new TB diagnostics on a routine basis.

Infection Control: best practices need to be scaled-up

In this context of high drug resistance, sound implementation of infection control measures is critical. In Ukraine, where MDR-TB prevalence among new and re-treatment cases reaches 16% and 45% respectively, a pilot project on infection control, supported by WHO and other partners, was started in 2006 in Donetsk oblast. The project included the creation of four MDR-TB wards, the renovation of five laboratories, training of health care workers, and involvement of local partners such as the sanitary-epidemiological services for routine monitoring and evaluation. In order to implement infection control measures at scale, national authorities were sensitized on infection control issues and orders or “prikaz” were developed and approved: the national policy on infection control is now in its final phase of elaboration.

The pilot experience also has several challenges:

- A lack of managerial capacity, financial resources and coordination among different players;
- Unnecessary prolonged hospitalization of TB patients with the risk to mix drug-resistant TB patients with people living with HIV in the majority of TB hospitals;
- A lack of implementation of infection control measures in HIV health facilities;
- Insufficient information, education and communication on infection control among health care workers: the majority still believe that one cannot be protected from infection if working in TB health facilities;
- Weak advocacy, communication and social mobilization due to poor involvement of civil society in TB issues in general;
- A need to develop checklists in line with international guidelines to facilitate routine monitoring and evaluation of infection control activities at facility level.

Isoniazid preventive therapy in high drug resistance settings: it works.

Only 9% of people living with HIV without active TB in the region were receiving isoniazid preventive therapy (IPT) in 2008 despite overwhelming evidence that IPT reduces the risk of active TB. The evidence that shows that most people will benefit from IPT with a background of high isoniazid mono-resistance was presented and discussed. There is no evidence about threshold prevalence of isoniazid resistance at which IPT risks exceed benefits. IPT does not promote isoniazid resistance when used to treat latent TB infection. Screening people living with HIV for TB is a cornerstone activity for scaling up IPT. It benefits those with active TB by earlier TB treatment initiation and decreases exposure of clinic attendees and health care workers to infectious TB cases. The meeting participants called upon the expedited implementation of the WHO Intensified Case Finding and Isoniazid preventive Therapy guidelines, which is based on four symptoms screening algorithm that can reliably allow clinicians to screen people to determine whether they are eligible for IPT or need further evaluation for diagnosing TB.

TB and HIV in people who use drugs: the neglected time bomb

More than a quarter of the HIV cases (27%) were diagnosed among people who inject drugs in 2008 in the region. In some countries, over 50% of people living with HIV are injecting drugs and HIV prevalence over 30% has been reported in people who inject drugs in many countries including Russia and
Ukraine. People who use drugs also have increased rates of TB irrespective of whether they live with HIV or not. People who use drugs should be treated like any other person with a medical need and they should have the right to evidence based services. However, they tend to be a marginalized group with restricted access to health information and life-savings interventions. Broad dissemination and implementation of the joint WHO/UNODC/UNAIDS guidelines for addressing TB/HIV in people who inject drugs is important to fill this gap. It is also important to de-stigmatize and decriminalize the behaviours associated with increased risk such as drug use. Failure to respond to the health needs of people who inject drugs and other risk groups will have an increased public health impact.

Best practices from the region need to be harvested and nurtured. For example, non-governmental projects in Ukraine and Kyrgyzstan and the Red Crescent in Kazakhstan show that it is possible to provide coordinated and comprehensive prevention, treatment, support and care services to people who inject drugs. Social support is of utmost importance as people who use drugs tend to be former prisoners and therefore lacking the necessary passports and registered residency address needed to access health care services in Eastern Europe and Central Asian countries.

HIV, TB and Hepatitis C convergence: Pandora’s box?

There is a growing concern that TB and HIV among people who use drugs is converging with hepatitis C further complicating the management of patients. Hepatitis C infection occurs in 70 to 100% of persons who acquired HIV from injection drug use worldwide. Hepatitis C is medically important because HIV makes all the stages in the course of hepatitis C worse beginning with the likelihood of developing persistent infection. However effective screening and testing is scarce especially in Eastern Europe and Central Asian countries, while treatment is extremely expensive and rarely available. Screening and testing is essential to support prevention by reducing spread to other individuals and to provide treatment to those who need it. Other prevention methods include harm reduction measures such as needle and syringe programmes and drug dependence treatment, particularly opioid substitution therapy that will reduce the spread of both HIV and hepatitis C. Prevention measures need to be intensified when it comes to hepatitis C as it is more transmissible than HIV by an order of magnitude. More clinical research is needed to identify best ways to manage TB and HIV along with Hepatitis C particularly in people who use drugs. Health care workers should be vigilant to earlier detect such convergence through establishment of effective screening measures.
Accelerating the implementation of collaborative TB/HIV activities in the WHO European Region

KEY RECOMMENDATIONS

Programming

► Ministries of Health in the region to take leadership to improve structural mechanisms to maximize collaboration and coordination between ministries, civil and prison services, national TB control, HIV/AIDS, harm reduction and drug dependence programmes and to ensure full engagement of civil society. Establishment of functional TB/HIV/drug use/prison coordinating committees to which all stakeholders are invited would accelerate integrated programming.

► TB and HIV/AIDS programmes to implement sustainable and integrated TB and HIV interventions that are patient centred and based on models that proved to be effective in the region and other regions of the world.

► HIV/AIDS programmes and HIV stakeholders to take the lead on scaling-up the implementation of TB screening and the provision of isoniazid preventive therapy.

► HIV/AIDS programmes to endorse early initiation of antiretroviral therapy in HIV-positive adults and adolescents, including pregnant women and to ensure adequate training of health care workers.

► TB programmes to discourage hospitalized treatment of drug susceptible TB patients and move towards ambulatory outpatient treatment to reduce unnecessary stress on health system, increase successful treatment outcomes and respect human rights of patients.

► National health authorities to strengthen HIV and TB surveillance systems and implement joint recording and reporting formats to adequately track progress in implementing collaborative activities. Surveillance data should capture and allow for comparison of TB and HIV outcomes among most at risk and vulnerable populations.

HIV testing and treatment scale-up for TB patients and suspects

► TB and HIV/AIDS programmes to increase access and uptake of HIV testing and counseling for all TB patients and TB suspects.

► HIV/AIDS programmes to scale-up voluntary, free of charge and confidential HIV testing and counseling services to tailor most at risk and vulnerable populations, expanding beyond clinical settings and involving civil society and non-governmental organizations in service delivery, with established linkage with HIV prevention, treatment and care services.

► HIV/AIDS programmes to promote the use of sensitive, specific rapid HIV tests to support efforts to increase access to and uptake of HIV testing and counseling.

► TB and HIV/AIDS programmes to scale-up uptake of co-trimoxazole preventive therapy and antiretroviral therapy to reduce mortality among HIV-positive TB patients and to prevent TB.

People who use drugs

► National health authorities to implement and scale-up a comprehensive package of nine interventions for harm reduction, preferably using “one-stop service” or integrated service models, that include:

► Needle and syringe programmes,

► Opioid substitution therapy and other drug dependence,

► HIV testing and counseling,

► Antiretroviral therapy,

► Prevention and treatment of sexually transmitted infections,

► Condom programmes,

► Information, education and communication for people who use drugs and their sexual partners,

► Vaccination, diagnosis and treatment of viral hepatitis

► Prevention, diagnosis and treatment of TB.

► National TB, HIV/AIDS and harm reduction programmes to implement the joint WHO/UNODC/UNAIDS guidelines9 for addressing TB/HIV in people who inject drugs to improve the capacity of drug user networks and services to address TB as part of the harm reduction response.

► Ministries of Justice to de-stigmatize and decriminalize drug use behaviors by revising legal framework accordingly.

KEY RECOMMENDATIONS

Prison settings

- National governments to move the responsibility for the prison health system from the Ministry of Justice or Interior or Security to the Ministry of Health or establish a strong coordination system that ensures the delivery of quality and coordinated health services to prisoners.
- Penitentiary health authorities to scale-up the provision of evidence-based and effective TB, HIV and harm reduction services in prison settings, including prevention, treatment, care and psycho-social support.
- National civil and penitentiary health authorities to improve referral from penitentiary to civilian health systems to ensure continuity of treatment and care on transfer in an out of places of detention.
- Ministries of Justice to undergo comprehensive penal reform to reduce custodial sentencing to decrease overcrowding, and improve prison sanitary conditions and infection control measures.

The Three Is for HIV/TB (Intensified case-finding for TB, Isoniazid preventive therapy and TB Infection control)

- TB, HIV/AIDS and harm reduction programmes to encourage health care workers to screen people living with HIV for TB at each visit using simple symptom-based algorithm, and either start TB treatment if appropriate or, once active TB has been excluded, provide isoniazid preventive therapy. Neither chest radiography nor the use of the Tuberculin Skin Test (TST) should be a requirement to initiate IPT for people living with HIV.
- HIV/AIDS and harm reduction programmes and penitentiary health authorities to urgently scale-up prevention of TB through isoniazid preventive therapy in health care facilities and in prison settings, including in areas of high level of isoniazid-resistance as evidence shows that IPT does work in those settings and does not promote further resistance.
- National civil and penitentiary health authorities to develop and implement integrated infection control plans and guidelines to ensure that all health-care facilities and other enclosed settings are safe from TB transmission through the implementation of effective TB infection control measures.

Financing

- Governments to increase national funding sources to ensure adequate scale-up of collaborative TB/HIV activities including harm reduction services by civil and prison health systems.
- International TB/HIV community to ensure that countries are aware of the requirements of the Global Fund regarding inclusion of TB/HIV collaborative activities in all TB and HIV proposals and focus on most at risk and/or vulnerable populations.

Follow-Up

- Regional stakeholders such as WHO Regional Office for Europe and UNAIDS should regularly monitor progress against these recommendations by:
  - Providing technical assistance,
  - Ensuring dissemination of guidance and norms, including in Russian language,
  - Advocacy,
  - Sharing best practices in the Region,
  - Including HIV and health system strengthening component in the regional plan against MDR-TB currently being developed.
Accelerating the implementation of collaborative TB/HIV activities in the WHO European Region

Overall organization of the meeting:
Delphine Sculier with contributions from Smiljka de Lussigny, Martin Donoghoe, Alasdair Reid, Caoimhe Smyth and Richard Zaleskis.

Meeting steering committee:
Annabel Baddeley (UNAIDS, Switzerland); Jacqueline Bataringaya (International AIDS Society, Switzerland); Monica Beg (UNODC, Austria); Valery Chernyavskiy (Global Fund to Fight AIDS, tuberculosis and malaria, Switzerland); Philippe Creach (Global Fund to Fight AIDS, tuberculosis and malaria, Switzerland); Masoud Dara (KNCV, Netherlands); Smiljka de Lussigny (WHO Regional Office for Europe, Denmark); Martin Donoghoe (WHO Regional Office for Europe, Denmark); Andrew Doupe (WHO, Switzerland); Haileyesus Getahun (WHO, Switzerland); Lasha Goguadze (IFRC, Switzerland); Reuben Granich (WHO, Switzerland); Christian Gunneberg (WHO, Switzerland); Christian Gunneberg (WHO, Switzerland); Fabienne Hariga (UNODS, Austria); Vahur Hollo (ECDC, Stockholm); Erin Howe (Open Society Institute, USA); Csaba Kodmon (ECDC, Stockholm); Zhanat Kosmukhamedova (UNODC, Austria); Konstantin Lezhentsev (All Ukrainian Network of People living with HIV, Ukraine); Davide Manissero; Lars Moller (WHO Regional Office for Europe, Denmark); Julie Pluie (International AIDS Society, Switzerland); Alasdair Reid (UNAIDS, Switzerland); Roxanne Saucier (Open Society Institute, USA); D. Sculier (WHO, Switzerland); Caoimhe Smyth (WHO, Switzerland); Annette Verster (WHO, Switzerland); Claire Wingfield (Treatment Action Group, USA); Richard Zaleskis (WHO Regional Office for Europe, Denmark).

Report writing team:
Delphine Sculier with contributions of Haileyesus Getahun and rapporteurs

Chairs and moderators:
Galina Sergeevna Alexeeva; Gordana Radosavljevic Asic; Victor Botnaru; Valery Chernyavskiy; Martin Donoghoe; Amiran Gamkrelidze; Haileyesus Getahun; Jarno Habicht; Hans Kluge; Ludmila Semenova; Andrei Slavuckij; Jeroen van Gorkom; Elena Voc, Anna Zakowicz.

Rapporteurs:
Silviu Ciobanu; Gayane Ghukasyan; Christian Gunneberg; Rafael Lopez; Lars Moller; Arta Kuli; Valiantsin Rusovich; Caoimhe Smyth; Javahir Sulemanova.

Administrative and secretarial support:
Rosalie Edma with contributions from Rebecca Martinez and Doina Lin.

Meeting participants:
B. Abdelkhakov; T. Abdullaev; T. Abdilayev; R. Aburabi; M. Aichelburg; G. S. Alexeeva; L. Aliev; M. Antilia; F. Apina; R. Argirova; Y. Argymbaev; V. Ashirova; G. R. Asic; N. Atabekov; L. Babenko; A. Baddeley; M. Balasanyan; A. Balkandijeva; A. Barua; S. Bazhan; N. Biloschytska; L. Blanc; A. Bloom; V. Botnaru; H. Bozkurt; I. Burduja; S. Čaplinskas; B. Abdulkhakov; T. Abdullaev; T. Aichelburg; G. S. Alexeeva; L. Aliev; M. Antilia; F. Apina; R. Argirova; Y. Argymbaev; V. Ashirova; G. R. Asic; N. Atabekov; L. Babenko; A. Baddeley; M. Balasanyan; A. Balkandijeva; A. Barua; S. Bazhan; N. Biloschytska; L. Blanc; A. Bloom; V. Botnaru; H. Bozkurt; I. Burduja; S. Čaplinskas; D. Chemtob; V. Chernyavsky; M. Chong; H. Chou; G. Durdyyeva; R. Dzhumaev; R. Edma; Dotsenko; A. Doupe; E. Drankou; O. Frolova; H. Gadirova; J. Gadoev; K. Gamakina; A. Gamkrelidze; H. Getahun; S. Gheorghita; G. Ghukasyan; E. Girardi; L. Goguadze; L. Goguadze; C. Goyon; R. Granich; A. Grant; L. Grigorieva; S. Grigoryan; M. Grishina; R. Gunderlach; C. Gunneberg; J. Habicht; Y. K. Haile; K. Hasanova; D. Havlir; A. Hornung-Pickert; A. Hovhannisyan; E. Howe; V. Hryn; E. Ibraim; V. Iljina; I. Ismailov; H. Jankuloski; E. Jimenez; F. Jochims; E. Kalieva; S. Kamilova; L. Karpenko; S. Karymbaeva; O. Khetylo; H. Kluge; A. Koshojeva; D. Kudelia; O. Kulchenko; A. Kuli; M. A. Lansang; Y. Lazarevich; N. V. Leonchuk; K. Lezhentsev; D. Lin; A. Lochoshvili; R. Lopez-Olarte; C. Lubinski; B. MacBeath; M. Madzhidov; J. Mandelbaum-Schmid; A. Manganela; M. Mardarescu; J. Martinoniene; J. Mayowa; C. Mears; R. Mehdiyev; C. Mgone; L. A. Mikhailova; K. Mitic; L. Moller; Z. Mustafayeva; H. Nakatani; D. Namuntamba; A. Naukokaite; H. Njoo; C. Nyirienda; R. O’Brien; A. Olshanskiy; S. Osipchik; N. Otswoma; S. Pak; D. Pashkevich; Y. A. Pavlov; E. Pisemskiy; I. Poliakov; H. A. T. Rahmanberdiyev; A. Reid; F. Rodicuova; D. Rollason; L. Rooväli; V. Rusovich; S. Rustamov; D. Rüütel; L. Saidganieva; K. Salovaara; D. Samarini; A. Sarang; I. Schelokova; S. Schoning; D. Sculier; L. Semenova; L. Severin; D. Shemerby; O. Sheyanenko; M. Shmelev; E. Skachkova; A. Skrahina; A. Slavuckij; V. Slessarev; C. Smyth; I. Sobolev; A. Solovieva; P. Sommerfeld; A. Stina; L. Storozhuk; J. Sulemanova; A. Sultanova; S. P. Surenovich; J. Syed; O. Tarasenko; A. Taylakova; K. Thompson; K. Todadze; Z. Taktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova; T. Tsertsvadze; G. Tsogt; T. Tumanov; Z. Toktosonov; S. Topchubashova.

TBHIV

Stop TB Partnership

For more information please consult: www.who.int/tb/en
For more copies please send requests to: tbdocs@who.int

© World Health Organization, 2010. All rights reserved. WHO/HTM/2010.9